about
Shugoshin is a Mad1/Cdc20-like interactor of Mad2Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRYAn item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriersTranscranial magnetic stimulation studies of sensorimotor networks in Tourette syndromeA synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersZotepine loading in acute and severely manic patients: a pilot studyThe risk of re-identification versus the need to identify individuals in rare disease researchImpact of the control for corrupted diffusion tensor imaging data in comparisons at the group level: an application in Huntington disease.Structural changes in the somatosensory system correlate with tic severity in Gilles de la Tourette syndrome.Multispectral brain morphometry in Tourette syndrome persisting into adulthood.Abnormal peripheral chemokine profile in Huntington's diseaseIncreased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.Imitation in patients with Gilles de la Tourette syndrome--a behavioral study.Motor-cortical interaction in Gilles de la Tourette syndromeWhat is the impact of education on Huntington's disease?Age-at-onset in Huntington disease.Abnormal motor cortex plasticity in premanifest and very early manifest Huntington diseaseAbnormal motor cortex excitability in preclinical and very early Huntington's disease.Antineuronal antibody status and phenotype analysis in Tourette's syndrome.An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.Models of Parkinson's disease.Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's diseaseCDC-48/p97 coordinates CDT-1 degradation with GINS chromatin dissociation to ensure faithful DNA replication.The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.Neuropsychiatry and White Matter Microstructure in Huntington's DiseaseBehavioral and affective disorders in Tourette syndrome.The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington DiseaseThe Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease.Current concepts in clinical radiation oncology.β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercisesTranscranial magnetic stimulation in Gilles de la Tourette syndrome.Consensus paper on short-interval intracortical inhibition and other transcranial magnetic stimulation intracortical paradigms in movement disorders.Dying cell clearance and its impact on the outcome of tumor radiotherapy.Neurophysiology in Huntington's disease: an update.Haplotype-based stratification of Huntington's disease.Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.Identification of extreme motor phenotypes in Huntington's disease.Predictors during childhood of future health-related quality of life in adults with Gilles de la Tourette syndrome.Rate of change in early Huntington's disease: a clinicometric analysis.
P50
Q24306351-1EB8A510-698D-4C9F-BE16-CBD6DFEA4986Q24598264-F76CEC39-0534-4836-9A9F-C5D328D0BDE6Q24615427-B5534F08-EB91-402B-BC46-218DA88C1FE1Q26998623-82789D68-3C52-4B80-996F-BFAF3DFA352EQ28271944-1A2621CE-DB45-4239-8062-DC9CCBA49FF9Q28273414-8BFA71C9-4187-471B-B79E-F47B2FEC8E00Q28595728-58B705A2-62AC-4ED3-A1F8-6431A69BE67CQ30846955-1C7BC0F3-D9A8-495F-B76E-896207021391Q33399022-9F1929A0-D2D3-4DB0-8CDF-177B0093BD15Q33744798-E048F597-00D8-411F-93D8-FD0279F9B448Q33985904-BE91D25D-DC17-4C02-83F5-EE0F52265754Q34063149-93AC04CE-7A05-4E8A-AE3C-1695EF9F2197Q34119997-1B585E04-5F09-4CEC-9F5F-C94E22E82F44Q34124933-A29A761E-DFB3-485F-ABBA-07889C4E73C2Q34172955-177B4DE8-CD5E-4772-9C9C-277B138C03C6Q34210139-E13B313C-C3B5-4DA3-B90C-937223D6A11EQ34382326-39B444B8-89D4-4CA4-84EA-E6BA606C83A0Q34386162-50B21B24-7EBA-4D2D-8FCE-5E22C925865FQ34630405-ACF85634-58A4-4AF3-8B39-D398BCFB21BBQ35135962-ACA9A3D7-421D-4CE0-ACA6-672E1FAA9DECQ35158085-8EF6F4FB-19CD-40FB-9DD5-B0983BA1B0E4Q35262146-D370DB83-06C0-4CC0-898D-D98344D0FFC0Q36192735-5C47E570-4B55-40F8-8275-E531ED6821B3Q36380974-3BE46C63-1EB7-4D45-BBF5-B1E398283705Q36384343-35C4B6F1-FE36-408E-B420-345E9DA64804Q36420951-73665D47-5EEA-4D1A-B852-02FDAC44CBABQ36559246-2981A1C1-0411-4CE8-9916-8C083E29F47BQ36579812-919AFE2E-5204-4270-92E8-9A74A75D8B94Q37603804-1101F50A-70BF-49C4-817D-7F533BAAE053Q37603963-7E357333-5565-4CD2-B39A-EC5F46D85FCBQ37631063-E28FC376-1879-4B28-B0A3-1848AFF6A3E3Q37632908-5B0F160B-71A2-445C-AE9B-362756127FC9Q37773012-2B640593-D7E2-4E1E-9E06-B383F28F0BE5Q38042950-6C94FD65-B005-4911-A28D-1461A02F3A2FQ38212035-9648C280-21FB-450A-8969-669921876457Q38612630-D75EF74B-6941-4215-8302-7C5BA2784656Q38729986-36691DEB-640A-421B-8A09-9DD2E2307B12Q39169547-4C436D42-91BF-4EB6-9C17-EFC77D46EE67Q39645983-91E30F56-7698-488D-8225-28FE5B39DF8CQ39685633-4A15A63B-8EA2-4420-A2AA-788EE9FC1838
P50
name
Michael Orth
@en
type
label
Michael Orth
@en
prefLabel
Michael Orth
@en